The Evaluation of the Effect of N-acetylcysteine in Improving Methadone Poisoning

The Evaluation of the Effect of N-acetylcysteine ??Combined With Therapeutic Effect of Naloxone in Improving Methadone Poisoning

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210222050462N1

Enrollment

Registered

2022-01-13

Start date

2021-05-20

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poisoning by Methadone. Poisoning by Methadone, undetermined

Interventions

Intervention 1: Intervention group:In this group, treatment performed by using Naloxone and N-acetylcysteine ??. N-acetylcysteine ??is applied in therapeutic doses which used in acetaminophen poiso

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who have a triad of opioid poisoning, including: loss of consciousness, hypoxia and Myotic pupil Have a positive methadone level in urinalysis (UA)

Exclusion criteria

Exclusion criteria: Patient dissatisfaction Subjects who use supplements and drugs with similar effects or interfering with Naloxone and N-acetylcysteine

Design outcomes

Primary

Measure	Time frame
Serum levels of Aspartate aminotransferase enzyme. Timepoint: Measurement of the variable before intervening and 5 days after beginning the treatment with N-acetylcysteine. Method of measurement: Measured by Pars Azmoun commercial kitson on blood serum with an autoanalyzer system (BT3000, Italy).;Serum levels of Alanine transaminase. Timepoint: Measurement of the variable before intervening and 5 days after beginning the treatment with N-acetylcysteine. Method of measurement: By Pars Azmoun commercial kits Measured on blood serum with an autoanalyzer system (BT3000, Italy).;Serum levels of Blood urea Nitrogen. Timepoint: Measurement of the variable before intervening and 5 days after beginning of treatment with N-acetylcysteine. Method of measurement: Measured by Pars Azmoun commercial kits on blood serum with an autoanalyzer system(BT3000, Italy).;Serum levels of Creatinine. Timepoint: Measurement of the variable before tntervening and 5 days after beginning of treatment with N-acetylcysteine. Method of measurement: Measured by Pars Azmoun commercial kits on blood serum with an autoanalyzer system (BT3000, Italy).;Serum levels of Uric acid. Timepoint: Measurement of the variable before the intervening and 5 days after beginning treatment with N-acetylcysteine. Method of measurement: By Pars Azmoun commercial kits Measured on blood serum with an autoanalyzer system(BT3000, Italy).;Serum levels of Malondialdehyde. Timepoint: Measurement of the variable before the intervention and 5 days after the beginning treatment with N-acetylcysteine. Method of measurement: To 50 µl of serum, 50 µl of 0.05% solution of BHT (Butylated hydroxytoluene) in 0.95% ethanol, 400 µl of 0.44 mM phosphoric acid and 100 µl of 42 mM thiobarbituric acid solution (TBA) is added for 1 hour. The temperature is incubated at 100 ° C and then the samples are placed on ice for 5 minutes and then the absorptions are read with a spectrophotometer.;Serum levels of Lactate dehydrogenase. Timepoin	—

Measure

Time frame

Serum levels of Aspartate aminotransferase enzyme. Timepoint: Measurement of the variable before intervening and 5 days after beginning the treatment with N-acetylcysteine. Method of measurement: Measured by Pars Azmoun commercial kitson on blood serum with an autoanalyzer system (BT3000, Italy).;Serum levels of Alanine transaminase. Timepoint: Measurement of the variable before intervening and 5 days after beginning the treatment with N-acetylcysteine. Method of measurement: By Pars Azmoun commercial kits Measured on blood serum with an autoanalyzer system (BT3000, Italy).;Serum levels of Blood urea Nitrogen. Timepoint: Measurement of the variable before intervening and 5 days after beginning of treatment with N-acetylcysteine. Method of measurement: Measured by Pars Azmoun commercial kits on blood serum with an autoanalyzer system(BT3000, Italy).;Serum levels of Creatinine. Timepoint: Measurement of the variable before tntervening and 5 days after beginning of treatment with N-acetylcysteine. Method of measurement: Measured by Pars Azmoun commercial kits on blood serum with an autoanalyzer system (BT3000, Italy).;Serum levels of Uric acid. Timepoint: Measurement of the variable before the intervening and 5 days after beginning treatment with N-acetylcysteine. Method of measurement: By Pars Azmoun commercial kits Measured on blood serum with an autoanalyzer system(BT3000, Italy).;Serum levels of Malondialdehyde. Timepoint: Measurement of the variable before the intervention and 5 days after the beginning treatment with N-acetylcysteine. Method of measurement: To 50 µl of serum, 50 µl of 0.05% solution of BHT (Butylated hydroxytoluene) in 0.95% ethanol, 400 µl of 0.44 mM phosphoric acid and 100 µl of 42 mM thiobarbituric acid solution (TBA) is added for 1 hour. The temperature is incubated at 100 ° C and then the samples are placed on ice for 5 minutes and then the absorptions are read with a spectrophotometer.;Serum levels of Lactate dehydrogenase. Timepoin

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPante A Ramezannezhad

Shahre-kord University of Medical Sciences

ramezannezhad.p@skums.ac.ir0098 38 32264825-41

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026